宝威

Oral: Jia Fan, Zhenggang Ren, et al. Phase 2 study of HLX10 (a novel anti-PD-1 antibody) plus HLX04 (an anti-VEGF antibody) in patients with advanced hepatocellular carcinoma

Oral: Jin Li, Shukui Qin, et al. Phase 2 study of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumours

Oral: Jin Li, et al. HLX04 (a bevacizumab biosimilar candidate) versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line therapy for metastatic colorectal cancer: a randomised, double-blind phase 3 study

Shukui Qin, Jin Li, et al. Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology 2021 39:15_suppl, 2566-2566. DOI: 10.1200/JCO.2021.39.15_suppl.2566

Lingying Wu, et al. Efficacy and safety evaluation of HLX10 (a recombinant humanized anti-PD-1 monoclonal antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy: A single-arm, open-label, phase 2 study. Journal of Clinical Oncology 2021 39:15_suppl, e17510-e17510. DOI: 10.1200/JCO.2021.39.15_suppl.e17510

Zeng X, et al. AB0197 EFFICACY AND SAFETY OF HLX01 COMBINED WITH METHOTREXATE IN CHINESE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD INADEQUATE RESPONSES TO METHOTREXATE: RESULTS OF A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY. Annals of the Rheumatic Diseases 2021;80:1122-1123. DOI:10.1136/annrheumdis-2021-eular.282